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doi:10.1016/j.ejvs.2008.04.010Abstract Objective: To compare the relative efficacy of polidocanol (Aetoxisclerol, Kreuss-
ler, Germany) when used as a foam or liquid in the treatment of saphenous incompetence.
Materials and methods: Multicentre, prospective, randomised controlled trial conducted in
patients with incompetence of the great saphenous vein (GSV) with a truncal diameter of
4e8 mm. The great saphenous vein was injected using a single injection 2e2.5 ml of either
3% polidocanol or sclerosant foam containing one-fifth 3% polidocanol to four-fifths air (DSS
technique). Clinical assessments and duplex ultrasound scanning were performed after 3
weeks and then every 6 months for 2 years. No re-injection was performed irrespective of
the immediate result. The main outcome measure was elimination of GSV reflux.
Results: Ninety-five patients participated in the study, 47 were randomised to the foam scler-
osant group and 48 to the liquid group. No significant difference between the 2 groups was
found regarding sex, age, height, weight and saphenous vein diameter. At 3 weeks, complete
elimination of reflux was obtained in 17 of the 48 patients (35%) who received liquid sclerother-
apy, versus 40 of the 47 subjects (85%) in the foam group (p< 0.001, Chi squared). The inci-
dence of immediate venous spasm and the length of the sclerotic reaction, occlusion
measured by echography, were significantly greater in the foam group. There was no differ-
ence in the incidence of ecchymosis, inflammatory reactions or other side effects. Follow-
up of 6, 12, 18 and 24 months confirms our early results published in 2003. In total only 5
patients were lost to follow-up at 2 years (all of them were in foam group). These patients31 433434; fax: þ33 231 433330.
u (C. Hamel-Desnos).
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Efficacy of polidocanol foam versus liquid 367were included in the final outcome analysis as treatment failures (success rates at 2 years: 53%
in foam group and 12% in liquid group).
Conclusion: The sclerosant foam used in this study was more than twice as effective as the
liquid from which the foam was prepared.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
In spite of interest in foamed sclerosing agents by some
authors in the 1930s and 1950s,1,2 these have only gained
widespread popularity in the recent past.3e6 While conven-
tional sclerotherapy was previously used mainly for small
diameter varices, large diameter veins, in particular saphe-
nous trunks, can now be treated using ultrasound guided
foam sclerotherapy.7e16 In 2003 we published the short
term results of the first randomised, prospective multi-
centre study comparing the efficacy of polidocanol foam
to liquid sclerosant in the treatment of the great saphenous
vein (GSV).13 This paper describes the 2-year follow-up
results from the study.
The main aim of this research was to compare the
relative efficacy of polidocanol (Aetoxisclerol, Kreussler,
Germany) when used as a foam or liquid in the treatment
of saphenous incompetence. The outcome was judged by
duplex ultrasound imaging to demonstrate the elimination
of venous reflux in the saphenous trunk. As secondary
objectives, the study examined differences in length of
occlusion measured by B mode ultrasonography, the rate
of recanalisation and incidence of side effects following
treatment.
Materials and Methods
The methods of this trial were previously published and are
be summarised as follows.
Inclusion criteria:
 18e80 years old
 written consent
 GSV insufficiency, truncal diameter of between 4 and
8 mm inclusive (reflux greater than 1 s; patient




 Mental or psychiatric disturbance
 Chronic hepatic, cardiac, renal or respiratory
insufficiency
 Pregnancy or breast feeding
 Location outside the geographic study area
 Allergy to polidocanol or lauromacrogol
 Personal history of DVT
 Progressive malignant disease
 Constitutional or acquired thrombophilia
 Absence of effective contraception
 Intolerance to alcohol.Study outline
After randomisation, patients were treated with a single
echo-guided GSV injection of 3% polidocanol (Aetoxi-
sclerol, Kreussler, Germany) in either foam or liquid
form. For veins of 4e6 mm in truncal diameter, 2 ml were
injected; 2.5 ml were injected in veins of 6e8 mm. The
mixture to produce the foam consisted of one part of 3%
polidocanol to 4 parts of sterile air and the technique
used was the DSS technique.11,13 Patients lay supine during
treatment. All injections were given under ultrasound guid-
ance and performed using the direct puncture
technique.13,17
The injection was given at the junction between the
upper and middle-third of the thigh.
No special precaution or manoeuvre was undertaken
after the sclerotherapy (no elevation of the lower limb, no
compression of the sapheno-femoral junction, no series of
dorsiflexions by the patient). There was no special post-
operative instruction regarding exercise and/or walking.
No compression was applied after the treatment; a class
2 compression stocking (15e20 mmHg) was only recom-
mended combined with paracetamol if secondary pain or
inflammation developed.
Patients were seen for clinical examination and duplex
ultrasound scanning after 3 weeks and then every 6 months
for 2 years. The endpoint of treatment failure was consid-
ered to have been reached if venous reflux persisted in the
GSV after initial treatment or recurred during the 2-year
follow-up period.
The main outcome measure was elimination of saphe-
nous reflux as assessed by duplex ultrasonography.
Secondary outcome measures were the length of saphenous
vein occluded by treatment assessed by B mode ultraso-
nography and the incidence of adverse events (painful
inflammation, deep vein thrombosis, cutaneous necrosis, or
any other adverse event).Statistical analysis
Descriptors used in this study were the mean and standard
deviation for quantitative variables, size and distribution
for qualitative variables. Statistical significance was
assessed by an ANOVA and contingency tables were ana-
lysed with a Chi squared test. Correlation between spasm
and sclerotherapy results was studied and the predictive
and negative values of the spasm were calculated. The 2-
year follow-up of the results between foam and liquid
sclerotherapy was analysed with KaplaneMeier survival
analysis. The level of statistical significance was taken to
be 0.05. All data process was done with SAS software 8.2
Version.
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The protocol was approved by the French Ethics Committee
in Medical Research (CCPPRB e Comite´ Consultatif de
Protection des Personnes dans la Recherche Biome´dicale)
of Haute Normandie on March 15, 2001. It complies with the
Declaration of Helsinki (1964) according to its latest version
(Hong Kong, 1989). Patients who gave informed written
consent were considered for inclusion in the study.Results
Between May 2001 and March 2002, 95 patients were
included in 6 Normandy phlebology centres of whom 7
were male and 88 female; 49 right GSV and 46 left GSV.
After randomisation, liquid was injected in 48 patients, 47
received foam. There were no significant differences
between the groups when considering age, weight, height,
ratio between sexes, diameter of saphenous vein (Table 1).
Injection was immediately followed by venous spasm in 15
of the cases injected with liquid (31%) and in 31 of those
injected with foam (66%) (p< 0.001).
3-Week follow-up
Elimination of saphenous reflux was successful in 17 of the
liquid injection group (35%) and in 40 of the foam group
(85%) p< 0.001. The length of occluded vein measured by
ultrasonography was also significantly longer in the foam
group (average lengthZ 9.1 cm in the liquid group versus
26 cm in the foam group) (p< 0.0001).Significance of immediate venous spasm13,18
Spasm at the time of injection was not associated with
therapeutic success in the liquid group. There was,
however, a strong correlation between spasm and success
in the foam group p< 0.0001, with a positive predictive
value of 100%. In the absence of spasm, negative predictive
value was poor (44%), treatment being immediately
successful in more than 1 out of 2 cases.Technical problems
In 1 case, extra vascular injection of a small quantity of
foam occurred, which was without clinical repercussions.Table 1 Foam versus liquid e Hamel-Desnos. Baseline
patient data in the 2 study groups
Liquid Foam
Age 55 S.D. 16 54 S.D. 14 NS
Weight (kg) 66 S.D. 10 67 S.D.10 NS
Height (cm) 163 S.D. 5.0 165 S.D. 6.3 NS
BMI 25 S.D. 3.6 24 S.D. 3.3 NS
Female (%) 94 92 NS
Saphenous diameter (mm) 5.3 S.D. 1.0 5.5 S.D. 1.2 NSIncidents and side effects
There were 2 immediate incidents: a vaso-vagal response
which resolved without treatment and a sensation of heat
in the mouth immediately following the injection. There
were no additional consultations for adverse effects. At 3
weeks there were 5 cases of persistent inflammation of the
thigh, 2 cases of bruising, with no difference between the 2
treatment groups. Pain was judged by the patient to be
absent in 84 cases, mild in 8 cases, moderate in 1 case and
serious in 2 cases, without significant differences in the 2
groups. No patient used analgesics.
Related adverse effects (NZ 6): 2 thrombophlebitis of
the leg (with extension of sclerosis to saphenous
tributaries), 1 of which was treated with compression and
NSAID, and 1 with thrombectomy and compression; 1 case
of asthenia lasting 15 days, which resolved without treat-
ment; 1 case of headache on the evening of the injection,
treated with aspirin; and 2 cases of pain in the thigh and
knee, 8 days post-injection, which resolved without treat-
ment. There were no cases of visual disturbance, chest
symptom, deep or superficial vein thrombosis or cutaneous
necrosis.
2-Year follow-up
86 patients were seen for all follow-up visits, 5 showed up
for some and 5 patients dropped out. The 5 patients lost to
follow-up were all in the foam group: 3 at 6 months, 1 at 1
year and 1 at 2 years.
After 3 weeks, only 17 ‘‘successes’’ were left in the
liquid group whereas there were still 40 in the foam group;
it is therefore not surprising that all patients who were lost
to follow-up were in the foam group.
At 2 years, the success rates (successZ no recanalisa-
tion) were 12% in the liquid group (4 patients) and 53% in
the foam group (25 patients). The patients lost to follow-
up were taken into account and considered as treatment
failures.
Fig. 1 presents a duration curve calculated with Kaplane
Meier’s method: the x-axis indicates the time (in weeks),
the y-axis the probable duration of the absence of reflux
(calculated according to KaplaneMeier’s method). The
Log Rank test (comparing the 2 curves) shows that the 2Figure 1 KaplaneMeier analysis of the immediate outcome
of treatment and 2 years of follow-up in the 2 groups. Propor-
tion of successful outcomes is shown on the vertical axis.
Efficacy of polidocanol foam versus liquid 369curves are statistically different. It can therefore be
concluded that the recurrence of reflux is more frequent
over time for the ‘‘liquid’’ group (p< 0.0001).
Evolution of vein diameter following recanalisation
At 6 months, recanalisation had occurred in 15 patients, 10
in the liquid and 5 in the foam group (p< 0.01). In these
patients, lumen diameter was on average 3.3 mm while
the saphenous vein had an initial average diameter of
5.4 mm (reduction: 38%). Reduction in diameter was
greater in the foam group (52%) than in the liquid group
(28%) (N.S.).Discussion
These 2-year follow-up outcomes confirm early results (1-
year follow-up or less),13,19e21 e.g. foam sclerosant is twice
as effective as the liquid despite containing 5 times less
sclerosing agent. The rate of immediate success in the
foam group (85%) is relatively low when compared to the
literature.7e10,12,14,15,22,23 This is probably due to the fact
that in this study, treatment consisted of only a single
injection small volume and no re-injection whatever the
immediate result. The goal, however, was not to measure
the efficacy of foam sclerotherapy, but to compare foam
to liquid. Spasm at the time of injection was predictive of
immediate success but the absence of spasm was a poor
negative predictor.
A follow-up period of 2 years might appear short when
the goal of treatment is improvement measured in tens of
years. This is true for treatments such as surgery, which are
meant to be definitive and where recurrences are difficult
to treat. Where sclerotherapy is concerned, this thinking
must be put into context. In the presence of recanalisation,
diameter has decreased and the dosage used to achieve
that result years earlier is known. Thus, treatment has
every chance of being quick and effective and re-treatment
is generally easier.
Conclusion
Use of polidocanol foam doubles the efficacy of GSV
sclerotherapy over the liquid form. Treatment is quick,
well tolerated and relatively stable over time. This is
a viable alternative to surgery and it would appear reason-
able to extend the indication to the small saphenous vein
and to post-surgery recurrences. Also noteworthy is the
advantageous cost/effectiveness ratio when compared to
surgical or thermal endoluminal techniques, making it an
excellent choice in countries where financial considerations
in the treatment of varices remain problematic. Several
authors have used foam made with a weaker concentration,
often titrated to 1%.23e26 Moreover, small volumes seem to
achieve good efficacy and are recommended.27 The next
step therefore would appear to be to determine dose to
be injected (concentration and volume) and method of
creating the foam in order to obtain the best effective-
ness/tolerance ratio. According to Jia’s literature review,28
more randomised controlled trials (RCTs) are necessary.Acknowledgements
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